Table 4. HRs Comparing the Risk of Lymphoma in Patients Exposed to Anti-TNF Monotherapy or Combination Therapy vs Thiopurine Monotherapy and in Patients Exposed to Combination Therapy vs Anti-TNF Monotherapy.
| Lymphoma Type | Exposed to Anti-TNF Monotherapy vs Exposed to Thiopurine Monotherapy | Exposed to Combination Therapy vs Exposed to Thiopurine Monotherapy | Exposed to Combination Therapy vs Exposed to Anti-TNF Monotherapy | |||
|---|---|---|---|---|---|---|
| Crude HR (95% CI) |
Adjusted HR (95% CI)a |
Crude HR (95% CI) |
Adjusted HR (95% CI)a |
Crude HR (95% CI)a |
Adjusted HR (95% CI)a |
|
| All Patients | ||||||
| All lymphoma | 0.76 (0.50-1.16) | 0.93 (0.60-1.44) | 1.75 (0.98-3.10) | 2.35 (1.31-4.22) | 2.30 (1.23-4.31) | 2.53 (1.35-4.77) |
| Hodgkin lymphoma | 0.80 (0.30-2.14) | 0.79 (0.28-2.20) | 4.10 (1.55-10.8) | 4.29 (1.62-11.3) | 5.14 (1.65-16.0) | 5.44 (1.72-17.2) |
| Non-Hodgkin lymphoma | 0.75 (0.47-1.20) | 0.96 (0.59-1.56) | 1.22 (0.58-2.56) | 1.74 (0.82-3.69) | 1.62 (0.74-3.59) | 1.81 (0.81-4.00) |
| Patients With Incident IBD | ||||||
| All lymphoma | 0.62 (0.22-1.76) | 0.64 (0.22-1.87) | 1.98 (0.64-6.14) | 2.51 (0.78-8.13) | 3.20 (0.86-12.0) | 3.95 (1.01-15.5) |
Abbreviations: HR, hazard ratio; IBD, inflammatory bowel disease; TNF, tumor necrosis factor.
a
Multivariable Cox models adjusted for baseline characteristics including sex, age, affiliation to Complementary Universal Health Insurance, IBD diagnosis and duration, exposure to methotrexate and aminosalicylates, comorbidities and time-dependent covariates including exposure to corticosteroids, and IBD-related hospitalizations and surgical procedures.